Ultragenyx Pharmaceutical Investor Relations Material

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focuses on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally. It biologic products include Crysvita (burosumab) as an antibody targeting fibroblast growth factor 23 for treatment of X-linked hypophosphatemia; Mepsevii as an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi like evinacumab for treating long-chain fatty acid oxidation disorders; Evkeeza (evinacumab) like ezetimibe for treating homozygous familial hypercholesterolemia.